Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/01/13 | 8-K | Current report filing |
|
40 | |
| 09/23/13 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
8 | |
| 08/14/13 | 8-K | Current report filing |
|
6 | |
| 08/13/13 | D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
4 | |
| 08/12/13 | 8-K | Current report filing |
|
7 | |
| 08/12/13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
42 |
| 08/12/13 | 8-K | Current report filing |
|
14 | |
| 08/05/13 | 8-K | Current report filing |
|
28 | |
| 06/19/13 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 06/19/13 | DEF 14A | Definitive proxy statements |
|
24 |
